Skip to main content
SpringerLink
Log in
Book cover

Antiangiogenic Agents in Cancer Therapy pp 427–439Cite as

Antiangiogenic Therapy of Renal Cell Carcinoma

  • Chapter

  • 1686 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Summary

The use of antiangiogenic therapy for the treatment of renal cell cancer (RCC) has revolutionized the treatment of a disease, which for the better part of the last generation lacked a highly effective therapy. Prior standard options such as interferon-alpha (IFN-α) or IFN-β were not much better than placebo and were associated with toxicities that worsened the quality of life of many patients. Interleukin-2 (IL-2), while able to induce complete responses in a small percentage of patients, was limited to those subjects who were young enough and healthy enough to tolerate this intensive hospital-based therapy. Appreciating the pathophysiologic role that angiogenesis plays in RCC, numerous investigations have been carried out with a variety of antiangiogenic agents. Superiority of these new drugs to the time-tested standards has been defined, which has resulted in the establishment of effective standard treatments that prolong life for patients with RCC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 55:10–30, 2005.

    PubMed  Google Scholar 

  2. Clark J, Atkins M, Urba W, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carincoma: a cytokine working group randomized trial. J Clin Oncol 21:3133–40, 2003.

    Article  PubMed  CAS  Google Scholar 

  3. Messing E, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21:1214–22, 2003.

    Article  PubMed  CAS  Google Scholar 

  4. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19:425–31, 2001.

    PubMed  CAS  Google Scholar 

  5. Amato R. Chemotherapy for renal cell carcinoma. Semin Oncol 27:177–86, 2000.

    PubMed  CAS  Google Scholar 

  6. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60, 1995.

    PubMed  CAS  Google Scholar 

  7. Duchene D, Lotan Y, Cadeddu J, et al. Histopathology of surgically managed renal tumors: analysis of a contemporary series. Urology 62:827–30, 2003.

    Article  PubMed  Google Scholar 

  8. Sudarshan S, Linehan W. Genetic basis of cancer of the kidney. Semin Oncol 33:544–51, 2006.

    Article  PubMed  Google Scholar 

  9. Chang S, Jeon S, Lee S, et al. Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma. Urology 58:904–8, 2001.

    Article  PubMed  CAS  Google Scholar 

  10. McDermott D, Regan M, Clark J, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–41, 2005.

    Article  PubMed  CAS  Google Scholar 

  11. Fyfe G, Fisher R, Rosenberg S, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688, 1995.

    PubMed  CAS  Google Scholar 

  12. Clifford S, Maher E. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res 82:85–105, 2001.

    Article  PubMed  CAS  Google Scholar 

  13. Linehan W. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol 170:593–94, 2003.

    Article  PubMed  Google Scholar 

  14. Na X, Wu G, Ryan C, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor supporessor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588–92, 2003.

    Article  PubMed  CAS  Google Scholar 

  15. Maher E, Kaelin WJ. von Hippel-Lindau disease. Medicine 76:381–91, 1997.

    Article  PubMed  CAS  Google Scholar 

  16. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94:1569–75, 2002.

    PubMed  CAS  Google Scholar 

  17. Kreig M, Haas R, Brauch H, et al. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF 2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435–43, 2000.

    Article  CAS  Google Scholar 

  18. Turner K, Moore J, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957–61, 2002.

    PubMed  CAS  Google Scholar 

  19. Gordon M, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor in patients with metastatic cancer. Proc ASCO 17:809a, 1998.

    Google Scholar 

  20. Yang J, Haworth L, Sherry R, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–34, 2004.

    Article  Google Scholar 

  21. Sini P, Wyder L, Schnell C, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 11:4521–32, 2005.

    Article  PubMed  CAS  Google Scholar 

  22. Hainsworth J, Sosman J, Spigel D, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889–96, 2005.

    Article  PubMed  CAS  Google Scholar 

  23. Bukowski R, Kabbinavar F, Figlin R, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol 24:4523a, 2006.

    Google Scholar 

  24. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer 92:1855–61, 2005.

    Article  PubMed  CAS  Google Scholar 

  25. Ratain M, Eisen T, Stadler W, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–12, 2006.

    Article  PubMed  CAS  Google Scholar 

  26. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trials of the raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:4510a, 2006.

    Google Scholar 

  27. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 24:4501a, 2006.

    Google Scholar 

  28. Motzer R, Michaelson M, Redman B, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24, 2006.

    Article  PubMed  CAS  Google Scholar 

  29. Motzer R, Rini B, Bukowski R, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–24, 2006.

    Article  PubMed  CAS  Google Scholar 

  30. Motzer R, Hutson T, Tomczak P, et al. Phase III randomized trial of sunitinib maleate (SU 11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 24:LBA3, 2006.

    Google Scholar 

  31. George D, Michaelson M, Oh W, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:1548a, 2003.

    Google Scholar 

  32. Thomas A, Morgan B, Horsfield M, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162–71, 2005.

    Article  PubMed  CAS  Google Scholar 

  33. Kuenen B, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9:1648–55, 2003.

    PubMed  CAS  Google Scholar 

  34. Lara P Jr, Quinn D, Margolin K, et al. SU5416 plau interferon alpha in advanced renal cell carcinoma: a phase II California Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9:4772–81, 2003.

    PubMed  CAS  Google Scholar 

  35. Rini B, Rixe O, Bukowski R, et al. AG-013786, a multi-target tyrosine kinase inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. Proc Am Soc Clin Oncol 23:4509a, 2005.

    Google Scholar 

  36. Dupont J, Camastra D, Gordon M, et al. Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 22:776a, 2003.

    Google Scholar 

  37. Batist G, Patanaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carincoma patients: report of a phase II trial with two dose levels. Ann Oncol 13:1259–63, 2002.

    Article  PubMed  CAS  Google Scholar 

  38. Escudier B, Venner P, Bukowski R, et al. Phase III trial of Neovastat in metastatic renal cell carcioma patients refractory to immunotherapy. Proc Am Soc Clin Oncol 22:844a, 2003.

    Google Scholar 

  39. Stadler W, Rosner G, Small E, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J Clin Oncol 23:3726–32, 2005.

    Article  PubMed  CAS  Google Scholar 

  40. Friedland D, Leon L, Manola J, et al. Carboxyamidotriazole (CAI) in patients with advanced renal cell cancer refractory to immunotherapy: an ECOG phase II trial. Proc Am Soc Clin Oncol 21:2424a, 2002.

    Google Scholar 

  41. Stadler W, Kuzel T, Shapiro C, et al. Mulyi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol 17:2541–45, 1999.

    PubMed  CAS  Google Scholar 

  42. Gordon M, Manola J, Fairclough D, et al. Low dose interferon-a2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc Am Soc Clin Oncol 22:4516a, 2004.

    Google Scholar 

  43. Hoekstra R, de Vos F, Eskens F, et al. Phase I safety, pharmacokinetics, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23:5188–97, 2005.

    Article  PubMed  CAS  Google Scholar 

  44. Gordon M, Mendelson D, Guirguis M, et al. ABT-510, an antiangiogenic, thrombospondin-1 mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase IB trial. Proc Am Soc Clin Oncol 22:780a, 2003.

    Google Scholar 

  45. Ebbinghaus S, Hussain M, Tannir N, et al. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. Proc Am Soc Clin Oncol 23:4607a, 2005.

    Google Scholar 

Download references

Authors
  1. Michael S. Gordon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scot W. Ebbinghaus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Genzyme Corporation, Framingham, MA

    Beverly A. Teicher PhD

  2. M. D. Anderson Cancer Center, The University of Texas, Houston, TX

    Lee M. Ellis MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Gordon, M.S., Ebbinghaus, S.W. (2008). Antiangiogenic Therapy of Renal Cell Carcinoma. In: Teicher, B.A., Ellis, L.M. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-184-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-184-0_25

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-870-6

  • Online ISBN: 978-1-59745-184-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation